From: Salpingectomy before assisted reproductive technologies: a systematic literature review
IVF TREATMENT | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors & Years | Patients | E2 (on hCG day) ± SD | p | Stimulation Lenght (Days ± SD) | p | No. Oocytes retrieved ± SD/range | p | No. Obtained Embryos ± SD | p | No. transferred Embryos ± SD/range | p | Implantation Rate % (N) | p | Pregnancy Rate % (N) | p | Ongoing pregnancy rate % (N) | p |
Lass et al. [1] | a) 29 SLP (ECP) Type: unilateral b) 73 no surgery (healthy subjects) | pmol/L a) 6.087 ± 2.889 b) 6.635 ± 2735 | ns | a) 12.3 ± 1.6 b) 13.1 ± 2.0 | ns | - General a) 9.9 ± 5.3 b) 9.9 ± 5.3 c) Ipsilateral ovary 3.8 ± 3.0 Controlateral ovary 6.0 ± 3.6 | a, b) ns c) .01 | n.r | - | a) 2.4 ± 0.5 b) 2.0 ± 0.7 | ns | n.r | - | a) 17.2 (5) b) 13.7 (10) | ns | n.r | - |
Dechaud et al. [2] | a) 30 SLP (HY) Type: not specified b) 30 no surgery (TF, HY) | pmol/L a) 2.699 b) 1.903 | ns | n.r | - | a) 10.1 ± 5.0 b) 10.5 ± 6.0 | ns | a) 5.2 ± 3.4 b) 4.8 ± 3.7 | ns | n.r | - | - First attempts a) 10.4 (5/48) b) 4.6 (2/43) - All attempts a) 13.4 (21/156) b) 8.6 (10/116) | ns | - Per cycle a) 23.7 (14/59) b) 16.3 (8/49) - Per oocyte retrieval a) 31.8 (14/44) b) 23.5 (8/34) - Per transfer a) 36.8 (14/38) b) 25 (8/32) | ns | a) 34.2 (13/38) b) 18.7 (6/32) | ns |
Bredkjaer et al. [3] | a) 139 SLP (HY) Type: 128 bilateral, 11 partial b) 139 no surgery (TF, no HY) | n.r | - | n.r | - | a) 9.3 b) 9.1 | ns | n.r | - | a) 2.1 b) 2.1 | ns | a) 19 b) 21 | ns | a) 40.3 (106) b) 40.5 (120) | ns | a) 21.7 (57) b) 21.6 (64) | ns |
Strandell et al. [4] | a) 116 SLP (HY) Type: not specified b) 88 no surgery (TF, HY) | n.r | - | a) 11.4 ± 2.2 b) 11.6 ± 2.9 | ns | a) 10.6 ± 5.9 b) 10.6 ± 6.1 | ns | a) 6.8 ± 4.8 b) 7.0 ± 4.9 | ns | a) 2.0 ± 0.3 b) 2.0 ± 0.4 | ns | - Per transfer cycle a) 22.8 (47/206) b) 18.8 (28/149) - Ultrasound visible HY a) 30 (21/70) b) 16.7 (13/78) | ns .05 | a) 36.6 (41) b) 23.9 (22) | .05 | a) 28.6 (32) b) 16.3 (15) | .05 |
Dar et al. [5] | a) 26 SLP (ECP) Type: 25 unilateral, 1 bilateral Control: same patients before surgery | n.r | - | Before surgery a) 10.81 ± 2.45 After Surgery a) 10.68 ± 2.57 | ns | Before surgery a) - Operated site 6.06 ± 3.85 - Non operated site 5.07 ± 3.08 After Surgery a) - Operated site 5.31 ± 4.22 - Non operated site 4.4 ± 3.68 | ns | n.r | - | Before surgery a) 3.56 ± 0.81 After Surgery a) 3.37 ± 0.8 | ns | After Surgery a) 23.07 | - | After Surgery a) 19.23 | - | n.r | - |
Strandell et al. [6] | Before surgery a) 26 SLP (general) b) 9 unilateral c) 17 bilateral After Surgery a) 26 SLP (general) b) 9 unilateral c) 17 bilateral | n.r | - | Before surgery a) 11 ± 2.4 b) 12.2 ± 2.4 c) 10.4 ± 2.3 After Surgery a) 11.2 ± 2.3 b) 12.2 ± 2.4 c) 10.6 ± 2.1 | ns | Before surgery a) 9.4 ± 5.9 b) 9.1 ± 4.4 c) 9.5 ± 6.7 After Surgery a) 8.7 ± 5.7 b) 7.7 ± 4.6 c) 9.2 ± 6.2 | ns | Before surgery a) 7.0 ± 5.6 b) 6.4 ± 3.9 c) 7.3 ± 6.5 After Surgery a) 5.9 ± 4.3 b) 5.3 ± 4.3 c) 6.2 ± 4.4 | ns | n.r | - | n.r | - | n.r | - | n.r | - |
Strandell et al. [7] | a) 103 SLP (HY) Type: 40 unilateral, 63 bilateral b) 82 no surgery (TF, HY) | n.r | - | a) 11.3 ± 2.1 b) 11.4 ± 2.6 | ns | a) 10.3 ± 5.4 b) 10.6 ± 5.4 | ns | a) 6.8 ± 4.1 b) 7.1 ± 4.4 | ns | a) 2.0 ± 0.3 b) 2.0 ± 0.3 | ns | n.r | - | ODD RATIO - Total group 1.7 - US visible HY 2.8 - US visible HY bilateral 6.9 | .05 | HAZARD R (BR) - Total group 2.1 - US visible HY 3.8 US visible HY bilateral 6.0 | .05 |
Surrey et al. [8] | a) 32 SLP (HY) Type: not specified b) 15 PTO (HY) c) 35 no surgery (TF no HY) d) 12 PTO (prior sterilization) | pg/mL a) 2.555 ± 219 b) 2.366 ± 282 c) 2.925 ± 259 d) 2.479 ± 281 | ns | a) 9.5 ± 0.2 b) 10.1 ± 0.4 c) 9.8 ± 0.2 d) 9.3 ± 0.3 | ns | a) 16.2 ± 1.2 b) 14.4 ± 1.8 c) 17.5 ± 1.8 d) 12.2 ± 1.3 | ns | n.r |  | a) 2.79 ± 0.2 b) 3.5 ± 0.4 c) 3.2 ± 0.2 d) 3.0 ± 0.3 | ns | n.r | - | a) 57.1 (16/28) b) 46.7 (7/15) c) 52.9 (18/34) d) 58.3 (7/12) | ns | n.r | - |
Tal et al. [12] | a) 26 SLP (ECP) Type: unilateral b) 52 no surgery (healthy subjects) | pmol /L a) 5189 ± 3310 b) 5631 ± 3512 | ns | a) 11.6 ± 3.1 b) 10.8 ± 2.5 | ns | a) 8.6 ± 5.3 b) 8.4 ± 4.9 | ns | a) 5.5 ± 3.4 b) 4.0 ± 2.3 | ns | n.r | - | n.r | - | n.r | - | n.r | - |
Gelbaya et al. [10] | a) 40 SLP (HY) Type: 16 unilateral, 24 bilateral b) 25 PTD Type: 9 unilateral, 16 bilateral c) 103 no surgery (TF, no HY) | pmol/L a) 8558 ± 4337.98 b) 11192.7 ± 4167.3 c) 9512.78 ± 4173.9 | .05 | a) 10.35 ± 1.92 b) 10.28 ± 1.02 c) 10.17 ± 1.37 | ns | a) 10.23 ± 6.08 b) 13.68 ± 5.17 c) 12.92 ± 8.75 | .05 a vs b | a) 6.78 ± 4.58 b) 8.52 ± 4.75 c) 7.80 ± 5.48 | ns | n.r | - | a) 18.2 (10/55) b) 12.8 (5/39) c) 11 (18/163) | ns | a) 17.5 (7/40) b) 20 (5/25) c) 16.5 (17/103) | ns | a) 17.5 (7/40) b) 16.0 (4) c) 13.6 (14) | ns |
Moshin & Hotineanu [11] | a) 60 SLP (HY) b) 78 POT (HY) c) 66 no surgery (HY) type: not specified | n.r | - | n.r | - | a) 10.4 ± 6.0 b) 10.2 ± 5.7 c) 9.8 ± 5.5 | ns | a) 7.0 ± 4.7 b) 6.9 ± 4.6 c) 6.8 ± 4.6 | ns | a) 3.4 ± 1.2 b) 3.4 ± 1.3 c) 3.5 ± 1.3 | ns | n.r | - | a) 38 (23/60) b) 40 (31/78) c) 12 (8/66) | .05 a,b vs c | n.r | - |
Kontoravdis et al. [9] | a) 50 POT (HY) b) 50 SLP (HY) c) 15 no surgery (HY) type: not specified | n.r. | - | a) 12.3 ± 2.4 b) 11.9 ± 2.5 c) 13 ± 1.9 | ns | a) 11.6 ± 4.9 b) 12.1 ± 5.0 c) 10.9 ± 5.1 | ns | a) 8.7 ± 3.9 b) 8.53 ± 4.0 c) 7.9 ± 5.1 | ns | a) 2.6 ± 0.6 b) 2.6 ± 0.6 c) 2.6 ± 0.8 | ns | a) 19.5 b) 24.8 c) 5.6 | .03 a vs c .007 b vs c | a) 44.4 b) 55.3 c) 14.3 | .04 a vs c .007 b vs c | a) 37.8 b) 48.9 c) 7.1 | .03 a vs c .004 b vs c |
Nakagawa et al. [17] | a) 11 PTD (HY) b) 6 SLP (HY) type: not specified | pg/mL a) 1553 ± 1468 b) 1530 ± 896 | ns | n.r | - | a) 5.3 ± 4.7 b) 7.5 ± 5.5 | ns | n.r | - | n.r | - | n.r | - | a) 45.5 b) 50.0 | ns | n.r | - |
Almog et al. [19] | Before surgery (HY, ECP) a) 36 SLP (22 unilateral, 14 bilateral) After Surgery a) 36 SLP | pg/mL Before surgery a) 1899.9 ± 185 After Surgery a) 1997 ± 231 | ns | Before surgery a) 10.5 ± 0.6 After Surgery a) 10.4 ± 0.4 | ns | Before surgery a) 10.2 ± 6.6 After Surgery a) 10.3 ± 7.4 | ns | n.r | - | n.r | - | n.r | - | n.r | - | n.r | - |
Orvieto et al. [18] | Before surgery (HY) a) 15 uni/bilateral After surgery b) 15 uni/bilateral | pg/mL a) 1,996 ± 885 b) 2,020 ± 981 | ns | b) 10.5 ± 1.7 a) 10.8 ± 1.5 | ns | a) 11.6 ± 5.9 b) 10.2 ± 6.1 | ns | n.r | - | a) 2.7 ± 1.1 b) 2.3 ± 0.7 | ns |  |  | a) 6.7 (1/15) b) 40 (6/15) | .05 | n.r | - |
Xi et al. [20] | Before surgery (ECP) a) 76 SLP - 44 unilateral - 32 bilateral After Surgery a) 76 SLP - 44 unilateral - 32 bilateral b) 80 no surgery (healthy subjects) | pg/mL Before surgery a) 2663.5 ± 1246 2446.9 ± 983.8° 2512.5 ± 1119.4 After surgery a) 2783 ± 1281.3 2860.8 ± 1509.7 2585 ± 1216.2 b) 2934.8 ± 1234.9 | ns | Before surgery a) 10.7 ± 1.5 11.1 ± 1.5 10.7 ± 1.6 After surgery: a) 11.1 ± 1.8 11 ± 1.3 10.8 ± 1.9 b) 11.1 ± 1.8 | ns | Before surgery a) 11.1 ± 5.4 11.3 ± 5.1 11.9 ± 6.0 After surgery a) 11.6 ± 4.1 11.1 ± 4.3 11.9 ± 5.5 b) 11.5 ± 4.4 | ns | Before surgery a) 8.3 ± 4.4 7.5 ± 2.9 8.2 ± 4.3 After surgery a) 8.4 ± 3.9 8.4 ± 4.0 8.4 ± 3.4 b) 8.0 ± 3.1 | ns | n.r | - | n.r | - | n.r | - | n.r | - |
Na et al. [21] | a) 41 SLP b) 56 sclerotherapy type: not specified | n.r | - | n.r | - | a) 6.2 ± 1.0 b) 12.1 ± 11 | ns | n.r | - | n.r | - | n.r | - | a) 40 (17/43) b) 38 (23/60) | ns | n.r | - |
Lin et al. [24] | a) 103 SLP (HY, ECP) b) 185 (prior sterilization, tuboplasty, PTO) type: not specified | pg/mL a) 2153 ± 1239 b) 2340 ± 1529 | ns | a) 8.8 ± 1.4 b) 8.8 ± 1.5 | ns | a) 7.4 ± 3.9 b) 7.6 ± 4.1 | ns | n.r | - | a) 2.5 ± 0.8 b) 2.5 ± 0.8 | ns | a) 21.4 (56/261) b) 21.0 (98/465) | ns | a) 53.5 (55/99) b) 43.5 (77/177) | ns | a) 30.3 (30/99) b) 25.4 (45/77) | ns |
Ni et al. [22] | a) 26 bilateral SLP b) 34 unilateral SLP c) 23 PTO d) no surgery (TF, no HY) | n.r | - | a) 8.15 ± 1.29 b) 8.21 ± 1.27 c) 8.83 ± 1.37 d) 8.18 ± 1.35 | ns | a) 9.15 ± 3.73 b) 11.59 ± 6.14 c) 10.70 ± 4.92 d) 10.82 ± 4.82 | ns | a) 6.04 ± 2.85 b) 7.74 ± 4.23 c) 7.22 ± 3.25 d) 7.57 ± 3.74 | ns | a) 1.96 ± 0.45 b) 2.03 ± 0.39 c) 2.0 ± 0.43 d) 1.96 ± 0.20 | ns | a) 51 (26/51) b) 30.4 (21/69) c) 39.1 (18/46) d) 28 (28/100) | - | a) 65.4 (17/26) b) 47.1 (16/34) c) 52.2 (12/23) d) 49 (25/51) | ns | LBR a) 61.5 (16/26 b) 41.2 (14/34) c) 52.2 (12/23) d) 45.1 (23/51) | ns |
Grynnerup et al. [25] | a) 16 SLP (HY) Type: (uni/bilateral) not specified b) 42 no surgery (TF, with or without HY) c) 13 no surgery (unexplained infertility, no HY) | n.r | - | n.r | - | a) 7 (3–31 range) b) 12 (3–30) c) 9 (9–38) | .05 a vs b | n.r | - | a) 2 (1–3) b) 2 (1–2) c) 2 (1–2) | ns | n.r | - | n.r | - | n.r | - |
Hill et al. [27] | Surgery Group (ECP) a) 36 unilateral SLP - pre-surgery - post-surgery Medical Group (ECP) b) 153 methotrexate - pre-treatment - post-treatment | n.r | - | n.r | - | a) - 13 (3–31) - 12 (3–31) b) - 14 (2–36) - 14 (0–35) | ns | n.r | - | n.r | - | n.r | - | a) 14 (39) b) 68 (44) | ns | a) 13 (33) b) 53 (35) | ns |
Pereira et al. [29] | a) 107MTX (ECP) → 88 IVF b) 37 unilateral SLP (ECP) → 22 IVF | n.r | - | a) MTX pre 9.55 ± 1.99 post 9.76 ± 2.33 b) SLP pre 9.63 ± 2.21 post 9.86 ± 1.93 | a) ns b) ns | a) MTX pre 12.4 ± 5.77 post 10.6 ± 5.51 b) SLP pre 12.2 ± 6.43 post 10.2 ± 4.23 | a) .03 b) ns | n.r | - | a) MTX pre 2.92 ± 1.24 post 2.95 ± 1.38 b) SLP pre 2.86 ± 1.19 post 2.81 ± 1.01 | a) ns b) ns | n.r | - | n.r | - | LBR a) MTX post 32.95 (29) b) SLP post 36.3 (8) | - |
Ye et al. [28] | a) 83 unilateral SLP b) 41 bilateral SLP c) 74 no surgery | pg/mL a) 38.3 ± 14.91 b) 41.41 ± 16.59 c) 36.49 ± 16.77 | ns | a) 9.6 ± 1.76 b) 9.39 ± 2.12 c) 9.78 ± 1.62 | ns | a) 7.83 ± 4.16 b) 6.98 ± 4.15 c) 8.42 ± 4.04 | ns | a) 3.39 ± 3.03 b) 3.15 ± 2.51 c) 3.5 ± 2.6 | ns | n.r | - | n.r | - | n.r | - | n.r | - |
Odesjo et al. [30] | a) 118 unilateral SLP b) 35 unilateral salpingotomy | n.r | - | n.r | - | a) 11.69 ± 5.59 b) 11.8 ± 6.1 | ns | n.r | - | a) 104 (88 %) b) 30 (85.7 %) | ns | n.r | - | a) 32 (27.1 %) b) 8 (22.9 %) | ns | LBR a) 21 (17.8) b) 7 (20) | ns |